Rhein reverses the diabetic phenotype of mesangial cells over‐expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway

Jm, Zheng; Jm, Zhu; Ls, Li; Zh, Liu

doi:10.1038/bjp.2008.26

Cited by 79 publications

(44 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, rhein was used in most of the Chinese patients with diabetic nephropathy. It was demonstrated to reverse the cellular hypertrophy, fibronectin synthesis, and excessive glucose uptake of the diabetic mesangial cells, by inhibiting the hexosamine pathway (29). Therefore, the use of two drugs may have additional benefits for patients with ORG.…”

Section: Discussionmentioning

confidence: 99%

Obesity-Related Glomerulopathy

Shen

Chen

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: Obesity-related glomerulopathy (ORG) is an increasing cause of end-stage renal disease, but evidence concerning the effects of treatments is rather limited. This study was aimed at exploring the renoprotective effects of weight loss on patients with ORG.Design, setting, participants, & measurements: A total of 63 patients with renal biopsy-proven ORG had food and exercise intervention in the physician-supervised weight loss program and were divided into three groups on the basis of the percentage of weight change from baseline to follow-up: significant weight loss (>3% reduction in body mass index [BMI]), stable weight, or significant weight gain (>3% increase). Metabolic parameters and renal lesions were evaluated regularly for 2 years.Results: After 6 months, 27 patients lost weight by 8.29 ؎ 4.00%, with a mean decrease in proteinuria of 35.3%, whereas 24 months later, 27 patients achieved a 9.20 ؎ 3.78% reduction in BMI and a 51.33% reduction in urine protein secretion. The levels of serum triglyceride, serum uric acid, and BP were also decreased. Contrarily, in patients with increased BMI, urine protein was increased by 28.78%. Correlation analysis showed proteinuria was associated with BMI, serum triglyceride, and uric acid, and multivariate regression analysis indicated the changes in BMI were the only predictor of proteinuria (P < 0.01).Conclusions: Weight loss intervention benefited remission of proteinuria in patients with ORG, whose function could not be replaced by conventional pharmacotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Obesity-Related Glomerulopathy

Shen

Chen

et al. 2010

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…WAS-406 (2-acetamido-1,3,6-tri-O-acetyl-2,4-dideoxy--D-xylo-hexopyranose) and Azaserine reduce cardiovascular effects caused by hyperglycemia as antioxidants rather than by inhibiting only the hexosamine pathway [123,124]. Rhein, an anthraquinone compound isolated from rhubarb, decreases hexosamine pathway and is helpful in treatment of experimental diabetic nephropathy [125]. Benfotiamine, which converts fructose-6 phosphate into pentose-5 phosphates, is another compound that reduces flux through the hexosamine pathway [126].…”

Section: Inhibition Of Ros Antioxidants and Hexosamine Pathway As Ementioning

confidence: 99%

Molecular mechanisms of Diabetic Retinopathy, general preventive strategies and novel therapeutic targets

Safi¹,

Qvist²,

Kumar³

et al. 2013

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

The growing number of people with diabetes worldwide suggests that diabetic retinopathy (DR) and diabetic macular edema (DME) will continue to be sight threatening factors. The pathogenesis of diabetic retinopathy is a widespread cause of visual impairment in the world and a range of hyperglycemia-linked pathways have been implicated in the initiation and progression of this condition. Despite understanding the polyol pathway flux, activation of protein kinase C (KPC) isoforms, increased hexosamine pathway flux, and increased advanced glycation end-product (AGE) formation, pathogenic mechanisms underlying diabetes induced vision loss are not fully understood. The purpose of this paper is to review molecular mechanisms that regulate cell survival and apoptosis of retinal cells and discuss new and exciting therapeutic targets with comparison to the old and inefficient preventive strategies. This review highlights the recent advancements in understanding hyperglycemia-induced biochemical and molecular alterations, systemic metabolic factors, and aberrant activation of signaling cascades that ultimately lead to activation of a number of transcription factors causing functional and structural damage to retinal cells. It also reviews the established interventions and emerging molecular targets to avert diabetic retinopathy and its associated risk factors.

show abstract

“…Ligustrazine is a strong scavenger of oxygen-free radicals and can reduce peroxide production. Rhubarb can increase toxin excretion from the gastrointestinal tract, improve metabolism, and suppress cell proliferation and extracellular matrix synthesis (Zheng et al, 2008). In addition, some studies show that C. sinensis and ginseng can help to alleviate proteinuria and hematuria, reduce immunocomplex in circulation, and alleviate glomerular injury mediated by immunity (Chen et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Yan-Shen capsule on advanced chronic kidney disease (CKD) patients: An open, randomized, prospective, comparative study

Yuan¹,

Hou²,

Guang³

et al. 2012

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

This study aimed to investigate the efficacy of Yan-Shen capsule, a traditional Chinese medicine compound, on patients with advanced chronic kidney disease (CKD). A randomized prospective clinical trial was conducted to investigate the efficacy of Yan-Shen capsule on hospital patients with advanced CKD (stages III to IV). Each group included 82 patients (males and females), and all patients were followed up every month for three years. From the Yan-Shen capsule group, 13 patients (16%) reached the endpoints of the study, 64 (78%) continued at stage IV or below, and 5 were not followed up. From the Niao-Du-Qing granules group, 18 patients (22%) reached the endpoints, 60 (73%) continued at stage IV or below, and 4 were not followed up. From the placebo group, 46 patients (56%) reached the endpoints, 30 (37%) continued at stage IV, and 6 were not followed up. As for the patients who reached the endpoints, a significant difference existed between the Yan-Shen capsule group and the placebo group (P < 0.05), but no significant difference was observed between the Yan-Shen capsule group and the Niao-Du-Qing granules group (P > 0.05). Annual serum creatinine (SCr) increase, glomerular filtration rate (GFR) decrease, and erythropoietin requirement of the Yan-Shen capsule group were much lower than those of the placebo or Niao-Du-Qing granules group. Both Yan-Shen capsule and Niao-Du-Qing granules had significant protective effects on residual renal function in advanced CKD and were able to delay the progression to dialysis without obvious side effects. Yan-Shen capsule may be superior to Niao-Du-Qing granules in terms of protecting residual renal function and modifying anaemia.

show abstract

Rhein reverses the diabetic phenotype of mesangial cells over‐expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway

Cited by 79 publications

References 42 publications

Obesity-Related Glomerulopathy

Obesity-Related Glomerulopathy

Molecular mechanisms of Diabetic Retinopathy, general preventive strategies and novel therapeutic targets

Efficacy of Yan-Shen capsule on advanced chronic kidney disease (CKD) patients: An open, randomized, prospective, comparative study

Contact Info

Product

Resources

About